Updates are available Correction dated 2020-02-07
Click to view Correction: https://doi.org/10.1038/s41598-020-59351-2
-
Authors
Takizawa, Hotake
Hara, Yuko
Mizobe, Yoshitaka
Ohno, Taisuke
Suzuki, Sadafumi
Inoue, Ken
Takeshita, Eri
Shimizu-Motohashi, Yuko
Ishiyama, Akihiko
Hoshino, Mikio
Komaki, Hirofumi
Takeda, Shin’ichi
Aoki, Yoshitsugu https://orcid.org/0000-0002-9038-7506
-
Funding
Funding for this research was provided by:
Grants-in-Aid for Research on Nervous and Mental Disorders
Japan Agency for Medical Research and Development (18ek0109239h0002)
Japan Agency for Medical Research and Development (18lm0203066h0001)
Japan Agency for Medical Research and Development (18lm0203069h0001)
MEXT | Japan Society for the Promotion of Science (18K07544)
Grants-in-Aid for Research on Nervous and Mental Disorders
- License Information
-
More Information
Article History
Received: 15 November 2018
Accepted: 12 February 2019
First Online: 7 March 2019
Change Date: 7 February 2020
Change Type: Correction
Change Details: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Competing Interests
: The National Center of Neurology and Psychiatry is now developing NS-065/NCNP-01, an exon 53 skipping drug for DMD with the Nippon Shinyaku Co., Ltd.
